Perrigo Company plc(PRGO) Stock Research - Grey Stern Research
Loading...

Perrigo Company plc (PRGO) Stock Analysis

$29.83 (-0.90%)

PRGO Financial Performance


Use the table below to view Perrigo Company plc's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q4 - 2023

Metric Value Ranking among Peers
Price $30.10 -
52 Week Low $25.77 -
52 Week High $40.28 -
Market Cap $4.1 Billion 3/13
Gross Margin 37% 12/13
Profit Margin -3% 11/13
EBITDA margin -1% 12/13
Q4 - 2023 Revenue $1.2 Billion 1/13
Q4 - 2023 Earnings -$32.3 Million 11/13
Q4 - 2023 Free Cash Flow $208.6 Million 1/13
Trailing 4 Quarters Revenue $4.7 Billion 1/13
Trailing 4 Quarters Earnings -$10.8 Million 11/13
Quarterly Earnings Growth -154% 12/13
Annual Earnings Growth 93% 7/13
Quarterly Revenue Growth 0% 10/13
Annual Revenue Growth 4% 8/13
Cash On Hand $751.3 Million 1/13
Short Term Debt $0 12/13
Long Term Debt $3.6 Billion 2/13

Perrigo Company plc Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Perrigo Company plc's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 11/13
PS 0.88 11/13
PB 0.86 11/13
PC 5.46 10/13
Liabilities to Equity 1.27 5/13
ROA 0.00 10/13
ROE 0.00 10/13
Current Ratio 1.79 8/13
Quick Ratio 0.12 9/13
Long Term Debt to Equity 0.76 5/13
Debt to Equity 0.76 5/13
Burn Rate 4.23 3/13
Cash to Cap 0.18 4/13
CCR -6.46 13/13
EV to EBITDA -450.63 13/13
EV to Revenue 1.50 11/13

Company Details

Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through two segments, Consumer Self-Care Americas and Consumer Self-Care International. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, marketing, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care in the United States, Mexico, Canada, and South America. The segment offers its products under the Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, Dr. Fresh, and Burt's Bees brand names. The Consumer Self-Care International segment develops, manufactures, markets, and distributes consumer self-care brands through a network of pharmacies, wholesalers, drug and grocery store retailers, and para-pharmacies in approximately 23 countries, primarily in Europe. The company also offers contract manufacturing services. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

CEO: Mr. Murray Kessler

Website: https://www.perrigo.com

Address: The Sharp Building, Hogan Place DUBLIN, DUBLIN

Exchange: New York Stock Exchange

Industry: Drug Manufacturers—Specialty & Generic

Perrigo Company plc Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Perrigo Company plc. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Prestige Consumer Healthcare Inc. PBH $3.2 Billion
Pacira BioSciences, Inc. PCRX $1.4 Billion
Collegium Pharmaceutical, Inc. COLL $1.1 Billion
Eagle Pharmaceuticals, Inc. EGRX $61.8 Million
Dr. Reddy's Laboratories Limited RDY $11.4 Billion
ANI Pharmaceuticals, Inc. ANIP $1.3 Billion
Amphastar Pharmaceuticals, Inc. AMPH $2.1 Billion
Phibro Animal Health Corporation PAHC $745.3 Million
Deciphera Pharmaceuticals, Inc. DCPH $2.2 Billion
Kamada Ltd. KMDA $308.6 Million
Elanco Animal Health Incorporated ELAN $8.5 Billion
Silver Spike Investment Corp. SSIC $69.7 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
PRGO Income Statements
Quarter Year Revenue Earnings
Q4 2023 $ 1.2 Billion -$32.3 Million
Q3 2023 $ 1.1 Billion $14.2 Million
Q2 2023 $ 1.2 Billion $8.4 Million
Q1 2023 $ 1.2 Billion -$1.1 Million
Q4 2022 $ 1.2 Billion -$12.7 Million
Q3 2022 $ 1.1 Billion -$49.4 Million
Q2 2022 $ 1.1 Billion -$65.1 Million
Q1 2022 $ 1.1 Billion -$2.4 Million

View All

PRGO Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q4 2023 $751.3 Million $10.8 Billion $3.6 Billion $4.8 Billion
Q3 2023 $598.3 Million $10.8 Billion $4.1 Billion $4.7 Billion
Q2 2023 $555.2 Million $11.0 Billion $4.1 Billion $4.8 Billion
Q1 2023 $553.0 Million $11.0 Billion $4.1 Billion $4.8 Billion
Q4 2022 $600.7 Million $11.0 Billion $4.3 Billion $4.8 Billion
Q3 2022 $468.7 Million $10.7 Billion $4.1 Billion $4.6 Billion
Q2 2022 $485.3 Million $10.9 Billion $4.1 Billion $4.8 Billion
Q1 2022 $2.0 Billion $10.4 Billion $3.5 Billion $5.1 Billion

View All

PRGO Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q4 2023 $208.6 Million $0 $208.6 Million
Q3 2023 $92.7 Million -$31.8 Million $43.1 Million
Q2 2023 $32.9 Million -$20.0 Million $2.2 Million
Q1 2023 -$3.8 Million -$23.2 Million -$47.7 Million
Q4 2022 $159.5 Million -$26.4 Million $132.0 Million
Q3 2022 -$7.4 Million -$49.7 Million -$1.5 Billion
Q2 2022 -$45.3 Million -$28.4 Million -$1.5 Billion
Q1 2022 $58.8 Million -$20.3 Million $2.0 Billion

View All